Abstracts tagged "Epidemiology"

Abstract Number: 1208 • ACR Convergence 2022
Development and Validation of a Prognostic Model for Methotrexate Discontinuation with Abnormal Monitoring Blood-test Results: A Cohort Study Using Data from Clinical Practice Research Datalink Gold and Aurum
Georgina Nakafero¹, Matthew J. Grainge¹, Tim Card¹, Maarten W Taal¹, Guruprasad P Aithal¹, Christopher P Fox², Christian Mallen³, Danielle van der Windt³, Richard Riley³ and Abhishek Abhishek¹, ¹University of Nottingham, Nottingham, United Kingdom, ²Nottingham University Hospital NHS Trust, Nottingham, United Kingdom, ³Keele University, Keele, United Kingdom
Background/Purpose: Patients established on long-term low-dose weekly methotrexate treatment undergo 3-monthly monitoring blood-tests to facilitate early detection of drug-related adverse events. Regular testing may not…
Abstract Number: 1475 • ACR Convergence 2022
Epidemiology of Acute Ischemic Stroke in Patients with Systemic Lupus Erythematosus
Uzair Khan¹, Izza Bazigh², Achint Patel³, Aaparna Singh³, Neha Ghalib³, Ghazi Farman⁴, Salman Muddassir³, Farrukh Zaidi⁵, Sami Mughni³ and Adam Grunbaum⁶, ¹HCA Healthcare Florida / USF Morsani College of Medicine GME Consortium / Oak Hill Hospital, Odessa, FL, ²HCA Florida Oak Hill Hospital, Spring Hill, FL, ³HCA Healthcare Florida / USF Morsani College of Medicine GME Consortium / Oak Hill Hospital, Spring Hill, FL, ⁴Rehman Medical College, Spring Hill, FL, ⁵HCA Healthcare Florida / USF Morsani College of Medicine GME Consortium / Oak Hill Hospital, Port Richey, FL, ⁶Gulf Coast Rheumatology, Trinity, FL
Background/Purpose: Vascular events, including cerebrovascular accidents (CVA) occur earlier and more frequently in patients with Systemic Lupus Erythematosus (SLE) compared with healthy individuals. Several studies…
Abstract Number: 1751 • ACR Convergence 2022
Diagnosing the Cardiovascular Risk of VIOXX: A Place for Rofecoxib in Pain Management
Judith Boice, Mark Corrigan and Bradford Sippy, Tremeau Pharmaceuticals, Inc, Concord, MA
Background/Purpose: Traditional NSAIDs (tNSAIDs) are effective in treating arthritis pain but can be limited by GI adverse events and general bleeding related to platelet inhibition.…
Abstract Number: 1919 • ACR Convergence 2022
Underdiagnosis and Undertreatment of Knee Osteoarthritis in Persons with Type 2 Diabetes: A Cross-sectional Study
Lauren King¹, Esther Waugh¹, Ian Stanaitis², Alanna Weisman¹, Baiju Shah¹, Lorraine Lipscombe¹ and Gillian Hawker¹, ¹University of Toronto, Toronto, ON, Canada, ²Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Knee osteoarthritis (OA) and type 2 diabetes commonly co-occur due to shared risk factors. Concomitant knee OA makes type 2 diabetes management, particularly engaging…
Abstract Number: 0462 • ACR Convergence 2022
Increasing Incidence of Large Artery Manifestations in Patients with Giant Cell Arteritis, a Population-based Cohort over 70 Years
Mohanad Elfishawi¹, Mahmut Kaymakci², Sara Achenbach³, Cynthia Crowson⁴, Tanaz Kermani⁵, Cornelia Weyand⁴, Matthew J. Koster¹ and Kenneth J. Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Rochester, MN, Rochester, MN, ⁴Mayo Clinic, Eyota, MN, ⁵University of California Los Angeles, Los Angeles, CA
Background/Purpose: Screening for large artery manifestations has been adopted by clinicians managing patients with Giant Cell Arteritis (GCA). The contemporary effect of the increased use…
Abstract Number: 0713 • ACR Convergence 2022
The Epidemiology, Clinical Outcomes, and Healthcare Resource Utilization of IgG4-Related Disease Among Commercially Insured People in the United States
Zachary Wallace¹, Gandarvaka Miles², Ekaterina Smolkina³, Natalia Petruski-Ivleva², Duane Madziva², Claire Cook¹, Xiaoqing Fu¹, yuqing zhang⁴, John Stone⁵ and Hyon Choi⁶, ¹Massachusetts General Hospital, Boston, MA, ²Sanofi, Unknown, ³Sanofi, Amsterdam, Netherlands, ⁴Massachusetts General Hospital, Quincy, MA, ⁵Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated condition that causes fibroinflammatory lesions, often presenting as pancreatitis, cholangitis, sialoadenitis, and retroperitoneal fibrosis. The epidemiology of IgG4-RD,…
Abstract Number: 0965 • ACR Convergence 2022
Pregnancy Outcomes in a Diverse Lupus Cohort
Julia Simard¹, Emily Liu², Eliza Chakravarty³, Amadeia Rector¹, Miranda Cantu⁴, Daniel Kuo⁵, Gary Shaw⁶, Maurice Druzin⁶, Michael Weisman⁷ and Monique Hedderson², ¹Stanford University School of Medicine, Palo Alto, CA, ²Kaiser Permanente Northern California’s Division of Research, Oakland, CA, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Global Lupus Support Group, Portage, MI, ⁵Kaiser Permanente, Redwood City Medical Center, Redwood City, CA, ⁶Stanford University School of Medicine, Palo Alto, ⁷Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Although the overall systemic lupus (SLE) patient population is racially and ethnically diverse, many study populations are homogeneous. We assembled a diverse group of…
Abstract Number: 1209 • ACR Convergence 2022
Impact of Change in Disease Modifying Antirheumatic Drug Therapy on Disease Activity Measures: Findings from a Large Contemporaneous Real-World Longitudinal Database of Psoriatic Arthritis Patients
Zhaohui Su¹, Lauren Stevens², Tom Brecht¹, Jessica Paulus¹ and Stefan Weiss³, ¹OM1, Inc., Boston, MA, ²OM1, Inc., Lexington, KY, ³OM1, Inc., Chapel Hill, NC
Background/Purpose: While many clinical trials provide direct comparisons between biologic disease modifying antirheumatic drugs (bDMARD) and nonbiologic DMARDs (nDMARD), there is a need for to…
Abstract Number: 1555 • ACR Convergence 2022
Comparison Between Clinical Features, Acute Phase Reactants, Imaging Between Takayasu and LV-GCA Patients at Diagnosis and During Follow-up in Italian Patients in Monocentric Study
Luigi Boiardi¹, PIERLUIGI MACCHIONI², Francesco Muratore¹, GIULIA KLINOWSKI³, ELENA GALLI¹, FEDERICA MACALUSO³, MASSIMILIANO CASALI¹, GIULIA BESUTTI¹ and Carlo Salvarani⁴, ¹Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy, ²IRCCS-S.Maria Nuova, Reggio Emilia, Italy, ³IRCCS REGGIO EMILIA, Reggio Emilia, Italy, ⁴Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Università di Modena e Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: Few studies compared the demographic, clinical, laboratory and imaging features, and outcomes of Takayasu arteritis (TAK) and large-vessel giant cell arteritis (LV-GCA). Aim of…
Abstract Number: 1753 • ACR Convergence 2022
Temporal Trends of SLE Mortality Among Various Ethnic Categories Across the United States: 2001-to 2020 Analysis from WONDER Database
Ikwinder Preet Kaur¹, Harjot Jagdey², hasan Mirza³, Waqar Mughal⁴ and Pankaj Bansal⁵, ¹Rutgers/Monmouth Medical Center, Long branch, NJ, ²BronxCare Hospital, Bronx, NY, ³Berkshire Medical Center, Pittsfield, MA, ⁴DHQ teaching hospital, Gujrat, Pakistan, ⁵Mayo Clinic, Eau Claire, WI
Background/Purpose: Racial disparities in SLE have been well described. Blacks are disproportionately affected, and have a higher incidence, disease severity, and mortality compared to Whites,…
Abstract Number: 1921 • ACR Convergence 2022
Association Between Knee Osteoarthritis and Health-Related Quality of Life in Persons with Type 2 Diabetes
Lauren King¹, Esther Waugh¹, Ian Stanaitis², Alanna Weisman¹, Baiju Shah¹, Lorraine Lipscombe¹ and Gillian Hawker¹, ¹University of Toronto, Toronto, ON, Canada, ²Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Knee osteoarthritis (OA) and type 2 diabetes commonly co-occur due to shared risk factors. Both knee OA and type 2 diabetes negatively impact health-related…
Abstract Number: L04 • ACR Convergence 2021
SARS-CoV-2 Infections Among Vaccinated Individuals with Rheumatic Disease: Results from the COVID-19 Global Rheumatology Alliance Provider Registry
Jean Liew¹, milena Gianfrancesco², Carly Harrison³, zara Izadi², Stephanie Rush², Lindsay Jacobsohn², Clairissa Ja², Saskia Lawson-Tovey⁴, Kimme Hyrich⁵, Laure Gossec⁶, Anja Strangfeld⁷, Loreto Carmona⁸, Martin Schaefer⁷, ELSA MATEUS⁹, Samar Al Emadi¹⁰, Claire Cook¹¹, Fatemah Abutiban¹², Dfiza Dey¹³, Emily Kowalski¹⁴, Marco Martinez-Martinez¹⁵, Naomi Patel¹¹, Evelyn Salido¹⁶, Jeffrey Sparks¹⁷, leanna Wise¹⁸, Suleman Bhana¹⁹, Wendy Costello²⁰, Rebecca Grainger²¹, Jonathan Hausmann²², Emily Sirotich²³, Paul Sufka²⁴, Zachary Wallace²⁵, Pedro Machado²⁶, Philip Robinson²⁷ and Jinoos Yazdany², ¹Boston University School of Medicine, Boston, MA, ²University of California San Francisco, San Francisco, CA, ³Lupus Chat, New York, NY, ⁴Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester Academic Health Science Centre, National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Sorbonne Universite, Paris, France APHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris, France, Paris, France, ⁷German Rheumatism Research Center (DRFZ Berlin), Epidemiology and Health Care Research, Berlin, Germany, ⁸Instituto de Salud Musculoesquelética, Madrid, Spain, ⁹EULAR, Lisboa, Portugal, ¹⁰Hamad Medical Corporation, Doha, Qatar, ¹¹Massachusetts General Hospital, Boston, MA, ¹²Rheumatology Unit, Department of Medicine, Jaber Alahmed Alsabah Hospital, KUWAIT, Kuwait, ¹³Rheumatology Unit , Department of Medicine and Therapeutics, University of Ghana Medical School, Korle Bu Teaching Hospital, Accra, Ghana, ¹⁴Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹⁵Instituto Mexicano del Seguro Social, San Luis Potosí, Mexico, ¹⁶University of the Philippines Manila, Manila, Philippines, ¹⁷Brigham and Women's Hospital, Boston, MA, ¹⁸University of Southern California, Los Angeles, CA, ¹⁹Pfizer, Montvale, NJ, ²⁰Irish Children's Arthritis Network (iCAN), Bansha, Ireland, ²¹University of Otago, Wellington, New Zealand, ²²Boston Childrens Hospital, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²³McMaster University, Hamilton, ON, Canada, ²⁴HealthPartners, Eagan, MN, ²⁵Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²⁶Centre for Rheumatology & Department of Neuromuscular Diseases, University College London; National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust; Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, United Kingdom, ²⁷University of Queensland School of Clinical Medicine, Herston, Queensland; Department of Rheumatology, Royal Brisbane and Women’s Hospital, Metro North Hospital and Health Service, Queensland, Australia., Brisbane, Australia
Background/Purpose: While COVID-19 vaccinations are a critical tool to prevent severe infections, poor immunogenicity in immunocompromised people threatens vaccine effectiveness. We analyzed clinical characteristics of…
Abstract Number: L17 • ACR Convergence 2021
Additional Heterologous versus Homologous Booster Vaccination in Immunosuppressed Patients Without SARS-CoV-2 Antibody Seroconversion After Primary mRNA Vaccination: A Randomized Controlled Trial
Michael Bonelli¹, Daniel Mrak¹, Selma Tobudic¹, Daniela sieghart¹, Peter Mandl¹, barbara kornek¹, elisabeth simader¹, Maximilian Koblischke¹, Helga Radner¹, thomas perkmann¹, helmuth haslacher¹, Margareta Mayer¹, philipp hofer¹, Kurt Redlich², Emma Husar-Memmer³, Ruth Fritsch-Stork⁴, Renate Thalhammer¹, Karin Stiasny¹, Stefan Winkler¹, Josef Smolen¹, Judith Aberle¹, Markus Zeitlinger¹, Leonhard Heinz¹ and Daniel Aletaha⁵, ¹Medical University of Vienna, Vienna, Austria, ²Hietzing Hospital, Vienna, Austria, ³Hanusch Hospital, Vienna, Austria, ⁴Sigmund Freud University, Utrecht, Netherlands, ⁵Medical University Vienna, Wien, Austria
Background/Purpose: Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)-induced coronavirus disease 2019 (COVID-19) has led to exponentially rising mortality, particularly in immunosuppressed patients, who inadequately respond to…
Abstract Number: 0094 • ACR Convergence 2021
Characteristics Associated with Severe Outcomes in Patients with Systemic Rheumatic Diseases Hospitalized for COVID-19 in New York City
Caroline Siegel¹, Jacky Choi², Debra D'Angelo², Paul Christos², Lindsay Lally¹, Parag Goyal², Lisa Mandl¹ and Medha Barbhaiya¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY
Background/Purpose: Patients with systemic rheumatic diseases (SRD) are potentially at increased risk of severe outcomes from SARS-CoV-2 infection due to their underlying immune dysregulation and…
Abstract Number: 0368 • ACR Convergence 2021
Geographical Prevalence of Family History in Patients with Axial SpA and Its Association with HLA-B27: Data from the Worldwide ASAS-perSpA Study
Miranda van Lunteren¹, Anne Boel¹, Clementina López Medina², Joachim Sieper³, Désirée van der Heijde⁴ and Floris van Gaalen¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, ³Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands
Background/Purpose: Research has shown that in patients with axial spondyloarthritis (axSpA), the most common form of spondyloarthritis (SpA) in a family history is axSpA. Moreover,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].